Stocklytics Platform
Asset logo for symbol APVO
Aptevo Therapeutics
APVO76
$4.41arrow_drop_down1.98%-$0.08
High Growth
Asset logo for symbol APVO
APVO76

$4.41

arrow_drop_down1.98%

Performance History

Chart placeholder
Key Stats
Open$4.68
Prev. Close$4.53
EPS-415.99
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.20M
PE Ratio-
LOWHIGH
Day Range4.18
4.68
52 Week Range0.14
21.56
Ratios
Revenue-
EBITDA Margin %-
EPS-415.99

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Aptevo Therapeutics (APVO)

Aptevo Therapeutics Inc (APVO) is a biotechnology company that specializes in the discovery, development, and commercialization of novel oncology therapeutics. The company's primary focus is on the development of antibody-based immunotherapies for the treatment of cancer. With a market capitalization of [APVO market cap], Aptevo is a relatively small player in the biotech industry. However, the company has shown promising results in its clinical trials and has attracted attention from investors. The stock price of APVO has seen significant fluctuations in the past year, with a 52-week range of [APVO 52-week range].
In terms of financial performance, Aptevo Therapeutics Inc has faced some challenges. The company's revenue has been inconsistent, and it has reported losses in recent quarters. However, Aptevo has a strong pipeline of potential drug candidates, which could drive future growth. The company's research and development efforts are focused on harnessing the power of the immune system to fight cancer. Aptevo's technology platform utilizes bispecific antibodies, which are designed to target both tumor cells and immune cells, enhancing the body's ability to eliminate cancer cells. This novel approach holds promise for the development of more effective and targeted cancer therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Marvin L. White
Headquarters
Seattle
Employees
45
Exchange
NASDAQ
add Aptevo Therapeutics  to watchlist

Keep an eye on Aptevo Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Aptevo Therapeutics 's (APVO) price per share?

The current price per share for Aptevo Therapeutics (APVO) is $4.41. The stock has seen a price change of -$0.09 recently, indicating a -1.99% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Aptevo Therapeutics (APVO)?

For Aptevo Therapeutics (APVO), the 52-week high is $21.56, which is 388.89% from the current price. The 52-week low is $0.14, the current price is 3.03K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Aptevo Therapeutics (APVO) a growth stock?

Aptevo Therapeutics (APVO) has shown an average price growth of -4.38% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aptevo Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Aptevo Therapeutics (APVO) stock price performance year to date (YTD)?

As of the latest data, Aptevo Therapeutics (APVO) has a year-to-date price change of -98.48%. Over the past month, the stock has experienced a price change of -58.9%. Over the last three months, the change has been -29.93%. Over the past six months, the figure is -77.93%. Looking at a longer horizon, the five-year price change stands at -99.96%.
help

Is Aptevo Therapeutics (APVO) a profitable company?

Aptevo Therapeutics (APVO) has a net income of -$17.41M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$28.88M. Furthermore, the EBITDA is -$24.21M.
help

What is the market capitalization of Aptevo Therapeutics (APVO)?

Aptevo Therapeutics (APVO) has a market capitalization of $2.21M. The average daily trading volume is 4.52, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level